Moolec Science Granted Continued Listing by Nasdaq Hearings Panel
Moolec Science announced that the Nasdaq Hearings Panel has granted the company's request for continued listing on The Nasdaq Stock Market, subject to certain conditions. The Panel acknowledged that the company satisfied the minimum bid price compliance period under Nasdaq Listing Rule 5550(b)(2) on January 16, following the effectiveness of its reverse stock split on January 5. The Panel will retain jurisdiction over the bid price matter through May 13, in accordance with its discretionary authority. The Panel also noted that the company filed its Annual Report on Form 20-F for the fiscal year ended June 30, 2025 on December 29, 2025, shortly following the hearing held on December 18, 2025. With respect to the minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1), the Panel recognized that the company has presented a plan that offers a reasonable expectation of regaining compliance within the applicable period. The continued listing determination is subject to the company satisfying certain conditions, including (i) the provision of updates to the Panel regarding the status of derecognition proceedings by the end of February, (ii) the delivery of updated pro forma financial information by the end of March, (iii) the timely public disclosure of actions taken to demonstrate compliance with Nasdaq's equity and continued listing requirements by May 13, and (iv) the company's demonstration, on or before May 13, of compliance with all continued listing requirements for the Nasdaq Capital Market. Moolec intends to fully satisfy the conditions outlined in the Panel's decision and remains focused on maintaining sustained compliance with Nasdaq's continued listing standards, strengthening its financial framework and advancing its strategic priorities.
Trade with 70% Backtested Accuracy
Analyst Views on MLEC
About MLEC
About the author
Rapt Therapeutics Acquired by GSK for $58 per Share, Valuing at $2.2 Billion
- Acquisition Deal: GSK has agreed to acquire Rapt Therapeutics for $58 per share, representing an estimated total equity value of $2.2 billion, which will significantly enhance GSK's market position in the biopharmaceutical sector.
- Stock Surge: Rapt Therapeutics' shares jumped 63.4% to $57.36 in pre-market trading, reflecting a positive market reaction to the acquisition, which may attract more investor interest in the company.
- Market Impact: This acquisition not only increases shareholder value for Rapt but may also prompt other biotech firms to consider similar strategic acquisitions to enhance their competitiveness and market share.
- Industry Outlook: With GSK's acquisition, Rapt's product development process is expected to accelerate, potentially leading to faster drug launches and further solidifying GSK's leadership position in the innovative pharmaceuticals market.
PainReform Ltd. (PRFX) Announces Name Change, Shares Surge 27.4%
- Significant Stock Surge: PainReform Ltd. shares rose 27.4% to $1.02 in pre-market trading following the announcement of a name change and expansion into diversified healthcare and AI-driven energy platforms, indicating strong market confidence in its new strategy.
- Diversification Strategy: The name change reflects the company's strategic shift towards healthcare and energy sectors, aiming to attract more investors and enhance brand recognition, thereby strengthening its competitive position in the market.
- Market Movements: In pre-market trading, Acco Group Holdings saw a staggering 219.4% increase, highlighting strong investor interest in high-growth potential companies, which may influence perceptions of other related stocks.
- Industry Trends: As the integration of healthcare and energy sectors accelerates, PainReform's strategic adjustments align with industry developments and could provide the company with long-term growth opportunities.
Gelteq Ltd Reports 22% Bioavailability Increase in Cannabinoid Oral Gel, Shares Surge 50.1%
- Bioavailability Improvement: Gelteq Ltd's oral gel delivery platform achieved over a 22% increase in bioavailability compared to an FDA-approved oil-based product in preclinical trials, indicating significant technological advantages that could enhance market acceptance and drive future sales growth.
- Stock Surge: Following this positive announcement, Gelteq's shares surged 50.1% in pre-market trading to $1.25, reflecting strong investor confidence in the new technology and its market potential.
- Enhanced Market Competitiveness: By improving product bioavailability, Gelteq not only meets the growing consumer demand but also positions itself more favorably in the competitive pharmaceutical market, potentially driving the company's long-term strategic development.
- Increased Investor Interest: With Gelteq's technological advancements and stock price increase, market attention on its future performance has significantly risen, likely attracting more investors and partners, thereby facilitating the company's capital operations and business expansion.
Moolec Completes 15-for-1 Share Consolidation, Reducing Outstanding Shares to 726,118
- Share Consolidation Implementation: Moolec Science completed a 15-for-1 share consolidation on January 5, 2026, converting every 15 shares of $0.10 par value into 1 share of $1.50 par value, reducing outstanding shares from 10,891,761 to 726,118, aimed at enhancing per-share value and improving capital structure.
- Market Reaction Adjustment: The consolidation became effective on Nasdaq on January 5, 2026, with all shareholders' positions automatically adjusted, which is expected to boost investor confidence and potentially attract more institutional investors.
- Simplified Shareholder Actions: The consolidation process requires no action from shareholders, as positions held through brokers will be automatically adjusted, ensuring liquidity and convenience while enhancing corporate governance standards.
- Future Growth Potential: While the consolidation does not directly impact operations, Moolec's focus on molecular farming and precision fermentation positions the company to attract more investment in the future to support the development of sustainable protein solutions.
Baidu Inc Proposes Spinoff of Kunlunxin H Shares, Stock Rises 12.3%
- Stock Surge: Baidu's announcement of a proposed spinoff of Kunlunxin (Beijing) Technology Co., Ltd. H shares for a separate listing on the Hong Kong Stock Exchange led to a 12.3% increase in its stock price to $146.69 in pre-market trading, indicating strong market enthusiasm for this strategic move.
- Spinoff Strategy: The spinoff aims to enhance Kunlunxin's independence and market valuation, which is expected to provide Baidu with more flexible capital operations and resource allocation, thereby strengthening its competitive position in the technology sector.
- Market Reaction: The spinoff news has sparked investor excitement, with the significant rise in Baidu's stock reflecting confidence in its future growth potential and likely attracting more institutional investors to its shares.
- Industry Impact: By pursuing this spinoff, Baidu can focus more on its core business while providing Kunlunxin with greater development space, which is anticipated to drive innovation and investment activity across the technology industry.
Moolec Gets Nasdaq Determination Notification
Nasdaq Compliance Issue: Moolec Science SA received a notification from Nasdaq regarding non-compliance with Listing Rule 5250(c)(1) due to the delayed filing of its Annual Report on Form 20-F for the fiscal year ending June 30, 2025.
Business Combination Challenges: The delay in filing is attributed to complexities arising from a recent business combination, which involved intricate accounting processes, including reverse acquisition accounting and asset valuation.
Stay of Suspension Request: Moolec has requested a stay of suspension from the Nasdaq Hearings Panel, which has temporarily allowed the company's shares to continue trading under the symbol "MLEC" until a hearing on December 18, 2025.
Company Overview: Moolec Science focuses on innovative protein solutions through Molecular Farming and precision fermentation, holding a diverse pipeline and a strong intellectual property portfolio, with operations across the U.S., Europe, and South America.
Rapt Therapeutics Acquired by GSK for $58 per Share, Valuing at $2.2 Billion
- Acquisition Deal: GSK has agreed to acquire Rapt Therapeutics for $58 per share, representing an estimated total equity value of $2.2 billion, which will significantly enhance GSK's market position in the biopharmaceutical sector.
- Stock Surge: Rapt Therapeutics' shares jumped 63.4% to $57.36 in pre-market trading, reflecting a positive market reaction to the acquisition, which may attract more investor interest in the company.
- Market Impact: This acquisition not only increases shareholder value for Rapt but may also prompt other biotech firms to consider similar strategic acquisitions to enhance their competitiveness and market share.
- Industry Outlook: With GSK's acquisition, Rapt's product development process is expected to accelerate, potentially leading to faster drug launches and further solidifying GSK's leadership position in the innovative pharmaceuticals market.
PainReform Ltd. (PRFX) Announces Name Change, Shares Surge 27.4%
- Significant Stock Surge: PainReform Ltd. shares rose 27.4% to $1.02 in pre-market trading following the announcement of a name change and expansion into diversified healthcare and AI-driven energy platforms, indicating strong market confidence in its new strategy.
- Diversification Strategy: The name change reflects the company's strategic shift towards healthcare and energy sectors, aiming to attract more investors and enhance brand recognition, thereby strengthening its competitive position in the market.
- Market Movements: In pre-market trading, Acco Group Holdings saw a staggering 219.4% increase, highlighting strong investor interest in high-growth potential companies, which may influence perceptions of other related stocks.
- Industry Trends: As the integration of healthcare and energy sectors accelerates, PainReform's strategic adjustments align with industry developments and could provide the company with long-term growth opportunities.
Gelteq Ltd Reports 22% Bioavailability Increase in Cannabinoid Oral Gel, Shares Surge 50.1%
- Bioavailability Improvement: Gelteq Ltd's oral gel delivery platform achieved over a 22% increase in bioavailability compared to an FDA-approved oil-based product in preclinical trials, indicating significant technological advantages that could enhance market acceptance and drive future sales growth.
- Stock Surge: Following this positive announcement, Gelteq's shares surged 50.1% in pre-market trading to $1.25, reflecting strong investor confidence in the new technology and its market potential.
- Enhanced Market Competitiveness: By improving product bioavailability, Gelteq not only meets the growing consumer demand but also positions itself more favorably in the competitive pharmaceutical market, potentially driving the company's long-term strategic development.
- Increased Investor Interest: With Gelteq's technological advancements and stock price increase, market attention on its future performance has significantly risen, likely attracting more investors and partners, thereby facilitating the company's capital operations and business expansion.
Moolec Completes 15-for-1 Share Consolidation, Reducing Outstanding Shares to 726,118
- Share Consolidation Implementation: Moolec Science completed a 15-for-1 share consolidation on January 5, 2026, converting every 15 shares of $0.10 par value into 1 share of $1.50 par value, reducing outstanding shares from 10,891,761 to 726,118, aimed at enhancing per-share value and improving capital structure.
- Market Reaction Adjustment: The consolidation became effective on Nasdaq on January 5, 2026, with all shareholders' positions automatically adjusted, which is expected to boost investor confidence and potentially attract more institutional investors.
- Simplified Shareholder Actions: The consolidation process requires no action from shareholders, as positions held through brokers will be automatically adjusted, ensuring liquidity and convenience while enhancing corporate governance standards.
- Future Growth Potential: While the consolidation does not directly impact operations, Moolec's focus on molecular farming and precision fermentation positions the company to attract more investment in the future to support the development of sustainable protein solutions.
Baidu Inc Proposes Spinoff of Kunlunxin H Shares, Stock Rises 12.3%
- Stock Surge: Baidu's announcement of a proposed spinoff of Kunlunxin (Beijing) Technology Co., Ltd. H shares for a separate listing on the Hong Kong Stock Exchange led to a 12.3% increase in its stock price to $146.69 in pre-market trading, indicating strong market enthusiasm for this strategic move.
- Spinoff Strategy: The spinoff aims to enhance Kunlunxin's independence and market valuation, which is expected to provide Baidu with more flexible capital operations and resource allocation, thereby strengthening its competitive position in the technology sector.
- Market Reaction: The spinoff news has sparked investor excitement, with the significant rise in Baidu's stock reflecting confidence in its future growth potential and likely attracting more institutional investors to its shares.
- Industry Impact: By pursuing this spinoff, Baidu can focus more on its core business while providing Kunlunxin with greater development space, which is anticipated to drive innovation and investment activity across the technology industry.
Moolec Gets Nasdaq Determination Notification
Nasdaq Compliance Issue: Moolec Science SA received a notification from Nasdaq regarding non-compliance with Listing Rule 5250(c)(1) due to the delayed filing of its Annual Report on Form 20-F for the fiscal year ending June 30, 2025.
Business Combination Challenges: The delay in filing is attributed to complexities arising from a recent business combination, which involved intricate accounting processes, including reverse acquisition accounting and asset valuation.
Stay of Suspension Request: Moolec has requested a stay of suspension from the Nasdaq Hearings Panel, which has temporarily allowed the company's shares to continue trading under the symbol "MLEC" until a hearing on December 18, 2025.
Company Overview: Moolec Science focuses on innovative protein solutions through Molecular Farming and precision fermentation, holding a diverse pipeline and a strong intellectual property portfolio, with operations across the U.S., Europe, and South America.
